Page 2 - Apic Bio News Today

Gene therapy clinical trial pipeline constitutes 250+ key companies continuously working towards developing 300+ gene therapies, analyzes DelveInsight LAS VEGAS, Nov. 2, 2022 /PRNewswire/

/PRNewswire/ -- DelveInsights Gene Therapy Competitive Landscape – 2022 report provides comprehensive global coverage of available, marketed, and pipeline...

Global Gene Therapies For Rare Diseases market is expected to reach US$ 11,441.6 Million by 2030, with a CAGR of 21.7% during a forecast period of 2022-2030.

Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 to 2030

Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 to 2030

The ALS Association Massachusetts Chapter Hosts Inaugural “CEO Soak” on June 10 in Downtown Boston Event Builds on Ice Bucket Challenge Legacy to Raise Funds for Local Families Living with ALS The ALS Association Massachusetts Chapter Norwood, Massachusetts, UNITED STATES NORWOOD, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- The ALS Association Massachusetts Chapter is encouraging local leadership to get soaked for a great cause. On Thursday, June 10, the organization wi...

By Grant Welker A firm making gene therapy for rare diseases that was co-founded by a UMass Medical School professor has won regulatory approval to continue research and investigatory work for an ALS therapy. Apic Bio, now based in Cambridges Kendall Square, was co-founded by Dr. Robert Brown Jr., a professor in UMass neurology department. Brown was a lead member of the team that discovered a particular enzyme as the first genetic mutation linked to ALS, or amyotrophic lateral scl...

Press release content from Business Wire. The AP news staff was not involved in its creation. Apic Bio Announces FDA Clearance of IND Application for Lead Gene Therapy Candidate APB-102 for the Treatment of SOD1 ALS April 21, 2021 GMT CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 21, 2021-- Apic Bio, Inc., an innovative gene therapy company developing novel treatment options for patients with rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Invest...

Posted on 387 Apic Bio Inc. today announced the appointment of Stephen Hoffman, MD, PhD, as Chairman of the Board. Dr. Hoffman has a distinguished career in life sciences spanning decades. Most recently he was the chief executive officer of Aerpio Pharmaceuticals, Inc., from 2017 to 2019 and has served as senior advisor to PDL BioPharma, Inc., since 2014. Prior to that, he was a managing director at Skyline Ventures, a venture capita...

Top story: Silencing of an ALS gene safely delivered to patients in UMass Medical School study Synthetic microRNA treatment targets mutant SOD1 gene that causes ALS By Jim Fessenden December 24, 2020 As this unprecedented year comes to a close, the Office of Communications is rerunning some of the big stories of 2020 that highlight the incredible work of the UMass Medical School community. From the first-in-the-nation early graduation of our medical students ...